Genmab (NASDAQ: GMAB) updates RSU vesting share price disclosure

Rhea-AI Filing Summary

Genmab A/S filed a Form 6-K to share a company announcement correcting the reported price for recent insider equity awards. A prior notice had shown a share price of DKK 0.00 for transactions involving managerial employees and related persons; the correct price is DKK 1,867.50 per share.

The correction covers acquisitions of Genmab shares due to vesting of restricted stock units granted on February 24, 2023 to President & CEO Jan van de Winkel, EVP & CFO Anthony Pagano, and board members Mijke Zachariasse, Martin Schultz, and Michael Kavanagh. All transactions occurred outside the market and reflect routine equity compensation vesting rather than open-market trading.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF MARCH 2026

COMMISSION FILE NUMBER 001-38976

Genmab A/S
(Exact name of Registrant as specified in its charter)

Carl Jacobsens Vej 30

2500 Valby

Denmark

+45 70 20 27 28
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F 

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273, 333-284876 and 333-293505) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit			Description of Exhibit
99.1			Company Announcement Dated March 2, 2026: Correction to Company Announcement No. 13 of March 2, 2026

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			GENMAB A/S
			BY:			/s/ Anthony Pagano
						Name: Anthony Pagano
						Title: Executive Vice President & Chief Financial Officer

DATE: March 2, 2026

Exhibit 99.1

Correction to Company Announcement No. 13 of March 2, 2026

COMPANY ANNOUNCEMENT

COPENHAGEN, Denmark; March 2, 2026 – Genmab A/S (Nasdaq: GMAB) - Correction: In Company Announcement no. 13/2026 regarding transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons it was reported that the share price associated with these transactions was DKK 0,00. The correct price is DKK 1,867.50.

The Company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the Company’s managerial employees and their closely associated persons.

This company announcement includes the vesting and net settlement of the restricted stock units granted to Jan van de Winkel and Anthony Pagano on February 24, 2023 (deferred RSUs as pertaining to annual bonus achievement).

Please find below a statement of such trading in shares issued by Genmab A/S

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Jan van de Winkel

2.

Reason for the notification

a)

Position/status

President & Chief Executive Officer

b)

Initial notification/Amendment

Amendment to Company Announcement no. 13 of March 2, 2026

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Genmab A/S

b)

LEI-code

529900MTJPDPE4MHJ122

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument Identification code

Share DK0010272202

b)

Nature of the transaction

Acquisition due to vesting of restricted stock units

c)

Price(s) and volume(s)

Price(s)

Volume(s)

DKK 1,867.50

567

d)

Aggregated information - Aggregated volume - Price

567 shares  DKK 1,867.50

e)

Date of the transaction

2026-03-02

f)

Place of the transaction

Outside the market

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby, Denmark Tel: +45 7020 2728
www.genmab.com
Company Announcement no. 14 Page 1/6 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122

Correction to Company Announcement No. 13 of March 2, 2026

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Anthony Pagano

2.

Reason for the notification

a)

Position/status

Executive Vice President & Chief Financial Officer

b)

Initial notification/Amendment

Amendment to Company Announcement no. 13 of March 2, 2026

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Genmab A/S

b)

LEI-code

529900MTJPDPE4MHJ122

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument Identification code

Share DK0010272202

b)

Nature of the transaction

Acquisition due to vesting of restricted stock units

c)

Price(s) and volume(s)

Price(s)

Volume(s)

DKK 1,867.50

200

d)

Aggregated information - Aggregated volume - Price

200 shares  DKK 1,867.50

e)

Date of the transaction

2026-03-02

f)

Place of the transaction

Outside the market

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby, Denmark Tel: +45 7020 2728
www.genmab.com
Company Announcement no. 14 Page 2/6 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122

Correction to Company Announcement No. 13 of March 2, 2026

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mijke Zachariasse

2.

Reason for the notification

a)

Position/status

Member of the Board of Directors

b)

Initial notification/Amendment

Amendment to Company Announcement no. 13 of March 2, 2026

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Genmab A/S

b)

LEI-code

529900MTJPDPE4MHJ122

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument Identification code

Share DK0010272202

b)

Nature of the transaction

Acquisition due to vesting of restricted stock units (as employee of Genmab B.V.)

c)

Price(s) and volume(s)

Price(s)

Volume(s)

DKK 1,867.50

64

d)

Aggregated information - Aggregated volume - Price

64 shares  DKK 1,867.50

e)

Date of the transaction

2026-03-02

f)

Place of the transaction

Outside the market

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby, Denmark Tel: +45 7020 2728
www.genmab.com
Company Announcement no. 14 Page 3/6 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122

Correction to Company Announcement No. 13 of March 2, 2026

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Martin Schultz

2.

Reason for the notification

a)

Position/status

Member of the Board of Directors

b)

Initial notification/Amendment

Amendment to Company Announcement no. 13 of March 2, 2026

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Genmab A/S

b)

LEI-code

529900MTJPDPE4MHJ122

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument Identification code

Share DK0010272202

b)

Nature of the transaction

Acquisition due to vesting of restricted stock units (as employee of Genmab A/S)

c)

Price(s) and volume(s)

Price(s)

Volume(s)

DKK 1,867.50

197

d)

Aggregated information - Aggregated volume - Price

197 shares  DKK 1,867.50

e)

Date of the transaction

2026-03-02

f)

Place of the transaction

Outside the market

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby, Denmark Tel: +45 7020 2728
www.genmab.com
Company Announcement no. 14 Page 4/6 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122

Correction to Company Announcement No. 13 of March 2, 2026

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Michael Kavanagh

2.

Reason for the notification

a)

Position/status

Member of the Board of Directors

b)

Initial notification/Amendment

Amendment to Company Announcement no. 13 of March 2, 2026

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Genmab A/S

b)

LEI-code

529900MTJPDPE4MHJ122

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument Identification code

Share DK0010272202

b)

Nature of the transaction

Acquisition due to vesting of restricted stock units (as employee of Genmab US, Inc.)

c)

Price(s) and volume(s)

Price(s)

Volume(s)

DKK 1,867.50

305

d)

Aggregated information - Aggregated volume - Price

305 shares  DKK 1,867.50

e)

Date of the transaction

2026-03-02

f)

Place of the transaction

Outside the market

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby, Denmark Tel: +45 7020 2728
www.genmab.com
Company Announcement no. 14 Page 5/6 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122

Correction to Company Announcement No. 13 of March 2, 2026

About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.

Contact:    
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs

T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations

T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby, Denmark Tel: +45 7020 2728
www.genmab.com
Company Announcement no. 14 Page 6/6 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122

FAQ

What did Genmab A/S (GMAB) correct in this Form 6-K filing?

Genmab corrected an earlier disclosure that showed a DKK 0.00 share price for insider RSU vesting. The company states the correct transaction price is DKK 1,867.50 per share for the affected equity awards, aligning reported figures with actual grant economics.

Which Genmab (GMAB) insiders were involved in the corrected RSU vesting transactions?

The corrected transactions involve President & CEO Jan van de Winkel, EVP & CFO Anthony Pagano, and board members Mijke Zachariasse, Martin Schultz, and Michael Kavanagh. Each received Genmab shares through vesting of previously granted restricted stock units.

What was the nature of the insider transactions disclosed by Genmab (GMAB)?

The transactions are acquisitions of Genmab shares resulting from vesting of restricted stock units granted as part of compensation. They are not open-market purchases or sales, but equity awards converting into shares, reported as occurring outside the market.

What is the corrected share price for Genmab (GMAB) RSU vesting events?

Genmab states the correct price for all listed vesting transactions is DKK 1,867.50 per share. This replaces the earlier, incorrect disclosure that showed a price of DKK 0.00, ensuring accurate reporting of the value of these equity awards.

Why did Genmab (GMAB) issue a correction to Company Announcement no. 13/2026?

Genmab issued the correction because Company Announcement no. 13/2026 reported an erroneous share price of DKK 0.00 for insider RSU vesting. The updated disclosure clarifies the correct price of DKK 1,867.50 for the affected transactions.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 119.0 KB